XPAR
POXEL
Market cap8mUSD
Oct 09, Last price
0.13EUR
1D
0.15%
1Q
-34.31%
Jan 2017
-98.08%
IPO
-98.83%
Name
Poxel SA
Chart & performance
P/E
—
P/S
1.08
EPS
—
Div yield, %
—
Shrs. gr., 5y
9.22%
Rev. gr., 5y
-51.60%
Revenues
7m
+234.98%
Net income
-18m
L-47.83%
CFO
-18m
L+25.95%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Poxel S.A., a biopharmaceutical firm in the clinical stage, is dedicated to creating innovative treatments for a range of metabolic disorders, including type 2 diabetes and various liver ailments. Its flagship product, Imeglimin, is an oral drug candidate that has successfully completed Phase III clinical trials in Japan. This promising medication is also undergoing Phase III trials in the United States and Europe for the management of type 2 diabetes. Imeglimin works by enhancing pancreatic beta cell function and mitigating insulin resistance, thereby reducing key cardiovascular and metabolic risk factors such as elevated blood lipid levels and excessive body weight. Additionally, Poxel is advancing PXL770, an activator of the adenosine monophosphate-activated protein kinase (AMPK) enzyme. This compound is currently in a Phase 2a clinical trial, targeting chronic metabolic conditions, notably liver diseases like non-alcoholic steatohepatitis (NASH). The company further expands its therapeutic portfolio through strategic licensing agreements. With Enyo Pharma S.A.S., Poxel is developing PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist, which is presently in a Phase II study for treating both hepatitis B and NASH. Another collaboration, with DeuteRx LLC, involves PXL065, a mitochondrial pyruvate carrier inhibitor, now in a Phase I clinical trial for the treatment of NASH. Established in 2009, Poxel S.A. maintains its headquarters in Lyon, France.
Key people
Thomas Kuhn
Chief Executive Officer, Director
Noah Beerman
Executive Vice President in charge of Business Development and President of Operations in the United States
Sebastien Bolze
Chief Operating Officer, Executive Vice President in charge of Project Management, Non Clinical and Manufacturing operations · since 2019
Pascale Fouqueray
Executive Vice President, in charge of Clinical Development and Regulatory Affairs · since 2019
Sophie Bozec
Senior Vice President in charge of R&D Pharmacology and Scientific Communication · since 2019
David Moller
Chief Scientific Officer · since 2020
Sylvie Bertrand
Vice President - Human Resources · since 2021
Fanny Bosa
Vice President - Finance and Administration · since 2023
Alexandre Bragadir
Director · since 2025
Yves Decadt
Director · since 2025
Pascale Boissel
Independent Director · since 2015
Independent Director · since 2015
Headquarters & legal address
129 RUE SERVIENT
TOUR PART-DIEU
LYON 69003
FR
TOUR PART-DIEU
LYON 69003
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||